Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group. de Fijter JW, et al. Among authors: russ g. Am J Transplant. 2017 Jul;17(7):1853-1867. doi: 10.1111/ajt.14186. Epub 2017 Feb 14. Am J Transplant. 2017. PMID: 28027625 Free article. Clinical Trial.
Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S; TRANSFORM Investigators. Tedesco-Silva H, et al. Among authors: russ g. Transplantation. 2019 Sep;103(9):1953-1963. doi: 10.1097/TP.0000000000002626. Transplantation. 2019. PMID: 30801548 Clinical Trial.
Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.
Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H. Pascual J, et al. Transplant Rev (Orlando). 2019 Oct;33(4):191-199. doi: 10.1016/j.trre.2019.07.001. Epub 2019 Jul 23. Transplant Rev (Orlando). 2019. PMID: 31377099 Review.
Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.
Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, Vanrenterghem Y, Krämer BK, Abramowicz D, Oppenheimer F, Pietruck F, Russ G, Karpf C, Undre N. Wlodarczyk Z, et al. Among authors: russ g. Am J Transplant. 2009 Nov;9(11):2505-13. doi: 10.1111/j.1600-6143.2009.02794.x. Epub 2009 Aug 14. Am J Transplant. 2009. PMID: 19681813 Free article. Clinical Trial.
FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.
Mulgaonkar S, Tedesco H, Oppenheimer F, Walker R, Kunzendorf U, Russ G, Knoflach A, Patel Y, Ferguson R; FTYA121 study group. Mulgaonkar S, et al. Among authors: russ g. Am J Transplant. 2006 Aug;6(8):1848-57. doi: 10.1111/j.1600-6143.2006.01404.x. Epub 2006 Jun 12. Am J Transplant. 2006. PMID: 16771816 Free article. Clinical Trial.
393 results